Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ES102 in combination with Toripalimab in advanced NSCLC
NCT06623136Phase 2Active, not recruiting
- Sponsor
- Elpiscience
- Start
- Apr 2025
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of inbrx-106 in non-small cell lung cancer (NSCLC), sponsored by Elpiscience. Primary endpoint: Objective Response Rate. Started Apr 2025; status: active, not recruiting.
02
Drugs
inbrx-106
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06623136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06623136.